Company intelligence / Profile preview
BioDiem
South Melbourne, VIC, Australiabiodiem.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BioDiem’s intranasal LAIV influenza vaccine technology is commercialized in India (Nasovac-S) and China (DeFluvac), with WHO prequalification and licensing. Other pipeline products are in preclinical or pending stages.
- Therapeutic areas
- Infectious DiseasesOphthalmology
- Modalities
- Live attenuated vaccineProphylactic vaccineSmall molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
World Health OrganizationBharat Biotech (India, Nasovac-S)Changchun BCHT Biotechnology (China, DeFluvac)Institute of Experimental Medicine (Russia)
Beyond the preview
Go deeper on BioDiem.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioDiem.